Cost analysis of DRG and PRG for the treatment of acute myocardial infarction during hospitalization;Analisi dei costi per DRG e PRG del trattamento dell'infarto miocardico acuto in regime di ricovero ospedaliero

Giornale Italiano di Cardiologia

Volumn 27, Issue 12, 1997, Pages 1290-1301

  Bezante, Gian Paolo ^a   Brunelli, Claudio ^a,c   Pasdera, Alberto ^b   Spallarossa, Paolo ^a   Merello, Maria Rosalia ^a   Rossettin, Pier ^a   Zorzet, Franco ^b   Caponnetto, Salvatore ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b Studio Pasdera e Zorzet SAS   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

Author keywords

Acute myocardial infarction; DRG; PRG

Indexed keywords

ACUTE HEART INFARCTION; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; COST BENEFIT ANALYSIS; DIAGNOSIS RELATED GROUP; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; REVIEW; TRANSLUMINAL CORONARY ANGIOPLASTY;

BUDGETS; COSTS AND COST ANALYSIS; DIAGNOSIS-RELATED GROUPS; HUMANS; INPATIENTS; MYOCARDIAL INFARCTION;

EID: 0031443678     PISSN: 00465968     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. AMERICAN HEART ASSOCIATION: Heart and stroke facts; 1996. Statistical supplement. Dallas, American Heart Association, 1996; 1-23.
2. GRUPPO ITALIANO PER LO STUDIO DELIA STREPTOCHINASI NELL'INFARTO MIOCARDICO (GISSI): Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986; 1: 397-402.
3. ISIS (SECOND INTERNATIONAL STUDY OF INFARCT SURVIVAL) COLLABORATIVE GROUP: Randomized trial of intravenous streptokinase, oral aspirin, both or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2: 349-360.
4. AIMS TRIAL STUDY GROUP: Effect of intravenous APSAC on mortality after acute myocardial infarction: preliminary report of a placebo-controlled clinical trial. Lancet 1988; 1: 545-549.
5. GRUPPO ITALIANO PER LO STUDIO DELIA STREPTOCHINASI NELL'INFARTO MIOCARDICO (GISSI-2): A factorial randomized trial of alteplase versus streptokinase and heparin versus no heparin among 12 490 patients with acute myocardial infarction. Lancet 1990; 336: 65-71.
6. ISIS (THIRD INTERNATIONAL STUDY of INFARCT SURVIVAL) COLLABORATIVE GROUP: Randomized comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41 299 cases of suspected acute myocardial infarction: ISIS-3. Lancet 1992; 339: 753-770.
7. THE GUSTO (GLOBAL UTILIZATION OF STREPTOKINASE AND TISSUE PLASMINOGEN ACTIVATOR FOR OCCLUDED CORONARY ARTERIES) INVESTIGATORS: An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329: 673-682.
8. GOLDMAN L: Cost and quality of life: thrombolysis and primary angioplasty. J Am Coll Cardiol 1995; 25: 38S.
9. AMERICAN HEART ASSOCIATION: Coronary risk handbook: estimating risk of coronary heart disease in daily practice. New York, American Heart Association, 1973.
10. ACC/AHA Guidelines for the Early Management of Patients with Acute Myocardial Infarction (special report). Circulation 1990; 82: 249-292.
11. THE TASK FORCE ON THE MANAGEMENT OF ACUTE MYOCARDIAL INFARCTION OF THE EUROPEAN SOCIETY OF CARDIOLOGY: Acute myocardial infarction: pre- and in-hospital management. Eur Heart J 1996; 17: 43-46.
12. ROGERS WJ, BOWLBY LJ, CHANDRA NC, ET AL: Treatment of myocardial infarction in the United States (1990 to 1993). Observations from the National Registry of Myocardial Infarction. Circulation 1994; 90: 2103-2114.
13. GHEORGHIADE M, RUZUMNA P, BORZAK S, HAVSTAD S, ALI A, GOLDSTEIN S: Decline in the rate of hospital mortality from acute myocardial infarction: impact of changing management strategies. Am Heart J 1996; 131: 250-256.
14. ROGERS WJ: What is the optimal tool to define appropriate therapy: the randomized clinical trial, meta-analysis, outcomes research? (Commentary). Curr Opin Cardiol 1994; 9: 401.
15. ASCH DA, HERSHEY JC: Why some health policies don't make sense at bedside. Ann Intern Med 1995; 122: 846-850.
16. ROTHWELL PM: Can overall results of clinical trials be applied to all patients? Lancet 1995; 345: 1616-1619.
17. ANTMAN EM, CANNON CP, MUELLER J, ET AL: Do clinical trial results influence physician drug use in myocardial infarction? (abstract) Circulation 1994; 90 (Suppl I): 167.
18. MARK DB, NAYLOR CD, HLATKY MA, ET AL: Use of medical resources and quality of life after acute myocardial infarction in Canada and in the United States. N Engl J Med 1994; 331: 1130-1135.
19. EVERY NR, FIHN SD, MAYNARD C, MARTIN JS, WEAVER D: Resource utilization in treatment of acute myocardial infarction: staff-model health maintenance organization versus fee-for-service hospitals. J Am Coll Cardiol 1995; 26: 401-406.
20. LUFT HS: How do health maintenance organizations achieve their savings? N Engl J Med 1978; 298: 1336-1343.
21. EVERY NR, LARSON EB, LIT WIN PE, ET AL: The association between on-site cardiac catheterization facilities and the use of coronary angiography after acute myocardial infarction. N Engl J Med 1993; 329: 546-551.
22. STERN RS, JUHN PI, GERTLER PJ, EPSTEIN AM: A comparison of length of stay and costs for health maintenance organization and fee-for-service patients. Arch Intern Med 1989; 149: 1185-1188.
23. ANTHONY RN, YOUNG DW: Management control in nonprofit organizations. Irwin, Homewood, 1988 (traduzione italiana: Controllo di gestione per gli enti pubblici e le organizzazioni non profit. Milano, McGraw-Hill, 1992).
24. DRUMMOND MF, STODDARDT GL, TORRANCE GW: Methods for the economic evaluation of health care programs. London, Mac Millan Press, 1987 (traduzione italiana: Metodi per la valutazione dei programmi sanitari. Milano, F. Angeli, 1993).
25. FINKLER SA: Essentials of cost accounting for health care organizations. Gaithersburg, Aspen Publication, 1994.
26. LEGGE 517/93, DECRETO MINISTERIALE 15 APRILE 1994: Determinazione dei criteri generali per la fissazione delle tariffe delle prestazioni di assistenza specialistica, riabilitativa ed ospedaliera.
27. PADERNI S, TARONI F, PIERGENTILI P, MARINO F, MARCADELLA L: Validare il metodo dei Diagnostic Related Group (DRG) come strumento di valutazione della produttività ospedaliera nella realtà del sistema sanitario italiano. Roma, Consiglio Nazionale delle Ricerche, Centro Italiano Studi e Indagini, 1987.
28. YOUNG DW, SALTMAN RB: Medical practice, case mix, and cost containment: a new role for the attending physician. J Am Medical Ass 1982; 12 (2): 801-805.
29. SEVERO CA: Les DRGs sont-ils le meilleur choix? Paris, DESS, 1989.
30. FRUTIGER P, FESSLER J-M: La gestion hospitalière médicalisée. Paris, ESF, 1991.
31. FETTER RB, SHIN Y, FREEMAN JL, AVERILL RF, THOMPSON JD: Case mix definition by diagnosis related groups. Med Care 1980; 18 (Suppl 2): 5-22.
32. PASDERA A: Lo zero-base budgeting: uno strumento per razionalizzare l'attività degli enti pubblici. Studi organizzativi 1988; 3-4.
33. ROTCH W, SCHELL W: Alexandria Hospital. University of Virginia Darden Graduate Business School Case, 1987, n. UVA-C-2007.
34. PASDERA A, ZORZET F: II budget per DRG. Uno strumento essenziale nella gestione della medicina interna. L'internista ospedaliero, settembre-dicembre 1995.
35. FINKLER SA: Flexible budget variance analysis extended to patient acuity and DRGs. Health Care Management Review 1985; 21-34.
36. PASDERA A, ZORZET F: Manuale per la rilevazione dei carichi di lavoro per DRG e PRG. Regione Liguria, 1995.